Research progress of pancreatic ductal adenocarcinoma with negative CA19-9 expression
10.3760/cma.j.cn113884-20250318-00089
- VernacularTitle:CA19-9表达阴性胰腺导管腺癌的研究进展
- Author:
Xiulun WANG
1
;
Rui BAI
1
;
Bei SUN
1
Author Information
1. 哈尔滨医科大学附属第一医院胰胆外科 肝脾外科教育部重点实验室，哈尔滨 150001
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Carbohydrate antigen 19-9;
Tumor marker
- From:
Chinese Journal of Hepatobiliary Surgery
2025;31(8):633-636
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is a relatively common malignant tumor, and the serum carbohydrate antigen (CA)19-9 is the most commonly used tumor marker in the diagnosis and treatment of PDAC. Elevated levels of CA19-9 in the serum are of significant importance in the diagnosis of most PDAC; however, some PDAC cases may exhibit negative expression of this serum antigen during the disease course. This article reviews recent clinical studies related to PDAC with negative CA19-9 expression, aiming to explore more diagnostic and therapeutic approaches for patients with CA19-9 negative PDAC.
